A clinical trial is a research study that finds new ways to treat a disease. The Arkansas Urology Research Center (AURC) participates in several clinical research trials to offer therapies to our patients that are not yet available at other local practices or clinics in Arkansas. These clinical trials are available to men and women of all ages.
You’ll find a few studies that we are actively enrolling our patients in listed below. We have additional studies not listed. Please contact the AURC at 501-219-8900 x 2002 if you are interested in learning more about these studies and/or other research opportunities.
Prostate Cancer
Blood Collectionat the Time of Prostate Biopsy
The purpose of this research is to see if a new, experimental blood test might help men with prostate cancer who are on active surveillance need fewer prostate needle biopsies.
A blood sample is collected in Little Rock at the lab or at the surgery center prior to your biopsy.
Observational Study of Patients of Being Treated ORGOVYX
SUNRISE-5-A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator’s Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC)
MOONRISE-1-A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations
SUNRISE-4-Janssen is conducting a Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy.
High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)
UR001-A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-301 (zalifrelimab) Administered Intravesically as Monotherapy and in Combination with Other Agents in Patients with Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)
PATAPSCO-This is an open-label, single-arm, multi-center, Phase IIIb US study exploring the combination of durvalumab and BCG (induction and maintenance) in participants with high-risk NMIBC
Strictures/BPH
The following trials are single-arm, prospective studies assessing semen quality after treatment with the Optilume DCB in men between 22 and 65 years of age.
eCoin® is the first FDA-approved tibial stimulator device for Urge Urinary Incontinence (UUI). The coin-sized device is placed under the skin, near the ankle during a safe and minimally invasive procedure.
Kidney Cancer
Detection of Clear Cell Renal Cell Carcinoma
An Expanded Access Program for the non-invasive detection of clear cell renal cell carcinoma (ccRCC) in patients with renal masses utilizing 89Zirconium-labelled girentuximab (89Zr-DFO-girentuximab)
Blood Collection at the Time of Prostate Biopsy
High-Risk 
A Phase 2 Study of IW‑3300 for the Treatment of Bladder Pain in Subjects with Interstitial Cystitis/Bladder Pain Syndrome
